Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna sales get lift from early nod for newest COVID shot
Moderna Inc. delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s COVID boosters.
Moderna Stock Jumps on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
The RSV Vaccine for Infants: Everything Parents Need to Know
The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...
BioPharma Dive12d
Pfizer sales of RSV vaccine ebb, but company gains market share
New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.
infectiousdiseaseadvisor.com10d
RSV Vaccine Abrysvo Approved for Adults Aged 18 to 59 at Increased Risk
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Investor's Business Daily on MSN4d
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?
Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit, sending Moderna stock higher in ...
Vietnam Investment Reviev13d
Clover announces positive clinical data for RSV Vaccine candidate SCB-1019 compared head-to-Head Versus GSK's AREXVY
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...
Taiwan News12d
AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval
HONG KONG SAR - Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30 th October that mRNA respiratory syncytial virus (RSV) vaccine developed by a ...
BioPharma Dive11d
GSK vaccine sales sink on lower demand for RSV, shingles shots
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...